کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
4251344 | 1283986 | 2011 | 10 صفحه PDF | دانلود رایگان |
Patients with high-risk neuroblastoma have a poor prognosis, especially in cases of recurrent or relapsed disease. Iodine-131–labeled meta-iodobenzylguanidine (131I-MIBG) can be an effective and relatively well-tolerated agent for the treatment of refractory neuroblastoma. Establishing an MIBG therapy program requires a great deal of planning, availability of hospital resources, and the commitment of individuals with training and expertise in multiple disciplines. Providing 131I-MIBG therapy requires physical facilities and procedures that permit patient care in compliance with the standards for occupational and community exposure to radiation. Establishment of a successful 131I-MIBG therapy program also requires a detailed operational plan and appropriate education for caregivers, parents, and patients.
Journal: Seminars in Nuclear Medicine - Volume 41, Issue 5, September 2011, Pages 354–363